Introduction {#section5-1753466618787385}
============

Bronchiectasis can be caused by diverse disease processes and mechanisms, resulting in the characteristic chronic cough, purulent sputum production and airway dilation.^[@bibr1-1753466618787385]^ The excessive retention of sputum in bronchiectasis contributes to the vicious circle of chronic respiratory infection with inflammation and more sputum production.^[@bibr2-1753466618787385]^ There are several factors that contribute to the abnormal mucociliary clearance characteristic of bronchiectasis, including pulmonary infection, increased mucus production, anomalous mucus composition, slowing of cilia and loss of ciliated cells.^[@bibr3-1753466618787385]^

The inhalation of hypertonic saline (HS) has been shown to be an effective method of promoting the removal of mucus from the airways, and a clinically accepted technique of physiotherapy in the treatment of various pulmonary diseases, including bronchiectasis and cystic fibrosis.^[@bibr4-1753466618787385],[@bibr5-1753466618787385]^ Several studies have shown that long-term inhalation of HS in patients with bronchiectasis is well-tolerated, improved quality of life (QoL) and decreased sputum viscosity; however, the comparison of HS to isotonic saline solutions gave disparate results.^[@bibr5-1753466618787385][@bibr6-1753466618787385]--[@bibr7-1753466618787385]^

Although a majority of bronchiectasis patients tolerate HS well, some report adverse events (AEs) that prevent longer-term treatment, including intense cough, bronchospasm, dyspnoea, throat irritation, chest tightness and salty taste. In these cases a possible treatment alternative is the combination of HS and hyaluronic acid (HA). Inhaled HA hydrates the airways, attenuates bronchial hyper-responsiveness, reduces inflammation and disrupts the biofilm associated with chronic infection.^[@bibr8-1753466618787385][@bibr9-1753466618787385]--[@bibr10-1753466618787385]^ Additionally, HA improves tolerability of HS by reducing its salty taste.^[@bibr11-1753466618787385]^

Although previous studies have demonstrated the potential safety and efficacy of the use of HS in patients with bronchiectasis,^[@bibr4-1753466618787385],[@bibr6-1753466618787385],[@bibr7-1753466618787385],[@bibr12-1753466618787385]^ there are limited data on the tolerability of HS in combination with HA and its impact specifically on these patients.^[@bibr13-1753466618787385]^ We hypothesized that addition of HA to HS could improve tolerability for those patients intolerant to HS alone. Therefore, the objective of this study was to evaluate the tolerability and effectiveness of the combination of 7% HS supplemented with 0.1% HA in patients diagnosed with bronchiectasis who were intolerant to treatment with 7% HS. Additionally, we assessed changes in QoL and compliance after four weeks of treatment, as well as any possible emergent AEs.

Methods {#section6-1753466618787385}
=======

This prospective, observational, open-label study was carried out by 11 pulmonologists in public teaching hospitals throughout Spain, and took place between November 2015 (inclusion of the first patient) and May 2017 (last visit of the last patient). The study protocol was approved by the ethical review committee of each participating centre. All patients were informed by the investigator about the research procedure and gave informed consent in accordance with good clinical practice guidelines and the Declaration of Helsinki.

Patient selection {#section7-1753466618787385}
-----------------

Consecutive patients were recruited by pulmonologists at their health centres. Inclusion criteria were: \>18 years old; previous diagnosis of bronchiectasis by high-resolution computed tomography; decision of the physician to start treatment with inhaled HS solution; clinically active sputum production greater than 30 ml every 24 h (semi-quantitative measurement); mean baseline forced expiratory volume in one second (FEV1) post-bronchodilator ⩾35% or ⩾1 L; and written informed consent to participate in this clinical research. The decision to start treatment with inhaled HS was made based on the physician's judgement according to routine clinical practice and was independent from the inclusion of the patient into the study.

Exclusion criteria were: exacerbations in the 4 weeks previous to inclusion in the study; treatment with oral antibiotics or systemic corticoids during the 4 weeks previous to inclusion in the study; previous events of haemoptysis caused by inhaled drugs; current treatment with inhaled HS; diagnosis of allergic bronchopulmonary aspergillosis^[@bibr14-1753466618787385]^ or cystic fibrosis, following guidelines;^[@bibr15-1753466618787385]^ patients unable, because of their medical or psychological condition, to perform necessary tests (e.g. spirometry) of the study; pregnant women; patients enrolled in other clinical studies; or patients with treated but uncontrolled arterial hypertension.

Main outcome {#section8-1753466618787385}
------------

The main variable of the study was the percentage of patients intolerant to HS but tolerant to HS+HA. Tolerance to HS+HA was assessed based on the patient's report on symptoms after inhalation (cough, pharyngeal irritation, salty taste, chest tightness, dyspnoea, wheezing and nausea), change in lung function (FEV1) after inhalation and the physician's judgement.

Study design {#section9-1753466618787385}
------------

This study was carried out in real-life conditions at the participating centres, imposing no restrictions on the participating physician who prescribed the treatment nor influencing any medical decisions. With the exception of the scales or questionnaires used as measurement instruments in this clinical investigation, the included patients were not given any diagnostic or follow-up intervention other than those followed in usual clinical practice.

Both solutions for inhalation were used with a nebulizer supplied by the health centre at the request of the doctor treating the patient, as is the usual practice in nebulized therapies. The use of jet or mesh electronic devices was allowed. The nebulizer nozzle was placed in the mouth, and the patient was asked to breathe normally. In all cases the recommendations of the instructions of use of the medical device were followed and the dose was adjusted to the requirements of each patient and to the clinical judgement of the doctor.

Spirometry measurements were obtained prior to the intervention, after the administration of a bronchodilator (20 min after two puffs of salbutamol), and after the administration of HS or HS+HA (30 min after inhalation).

Data were collected during three visits to determine tolerability of the treatment ([Figure 1](#fig1-1753466618787385){ref-type="fig"}):

-   In the basal visit (V0) the patients were administered HS and evaluated (see below). Tolerant patients continued with this treatment for 4 weeks, while intolerant patients were offered to start treatment with HS+HA one week later (visit 1, V1) to allow the patient to recover from symptoms caused by HS.

-   In visit 1 (V1), those patients intolerant to HS in V0 were evaluated for their tolerance to HS+HA. Tolerant patients were asked to remain on this treatment for 4 weeks.

-   In the final visit (V2), after 4 weeks of treatment with either HS or HS+HA, patients were evaluated for their tolerability of either treatment.

![Flow chart of the study.](10.1177_1753466618787385-fig1){#fig1-1753466618787385}

### Criteria of tolerability {#section10-1753466618787385}

We assessed tolerability to HS or HS+HA in each of the visits according to three parameters. The patient was asked to complete a seven-question, Likert-type questionnaire to assess tolerability to the treatment within 15 min after inhaling HS for the first time. The questionnaire evaluated cough, pharyngeal irritation, salty taste, chest tightness, dyspnoea, wheezing and nausea. The responses to each question ranged from "0" (nothing) to "3" (very much). The patient was scored as intolerant if, first, they answered "2" or "3" to any of the questions in the questionnaire; and/or, second, if in post-treatment spirometry the mean baseline FEV1 decreased by at least 15%; and/or, third, as judged by the physician supervising the test.

Quality of life and therapeutic compliance {#section11-1753466618787385}
------------------------------------------

QoL was self-evaluated by the patients in each of the visits by the Spanish-validated versions of the Quality of Life Questionnaire Bronchiectasis (QOL-B-Sp-V3.0) and the Leicester Questionnaire.^[@bibr16-1753466618787385],[@bibr17-1753466618787385]^ The QOL-B-Sp-V3.0 consists of two sections that evaluate QoL (28 items) and respiratory symptoms (9 items). The Leicester Questionnaire assigns a score based on the physical, social and psychological impact of the cough, and assesses its frequency and severity. It consists of 19 items with seven-point, Likert-type responses.

In addition, data on the patient's therapeutic compliance were collected on the final visit through the Morisky--Green (completed by the patient) and the Haynes--Sackett (completed by the doctor) tests.^[@bibr18-1753466618787385],[@bibr19-1753466618787385]^

AEs were documented by the investigator at each visit, and their relationship to the treatment was evaluated.

Statistical analysis {#section12-1753466618787385}
--------------------

### Sample size calculation {#section13-1753466618787385}

The sample size was calculated based on a previous study of cystic fibrosis patients, in which it was observed that the percentage of patients intolerant to HS but tolerant to HS+HA was 21.0%.^[@bibr13-1753466618787385]^ Assuming the expected proportion of non-tolerant patients to be 21%, and with a 95% confidence interval calculated with the exact (Clopper--Pearson) formula, we found that a sample size of 125 patients would provide an accuracy of ±7.5% in the estimation of the percentage of patients who do not tolerate HS+HA. Allowing for 10% patient loss because of invalid data or drop-out, we estimated that the target number of patients to be recruited was *N* = 139.

### Data analysis {#section14-1753466618787385}

Categorical variables were described by absolute and relative frequencies, including the 95% confidence interval. Variables were tabulated as mean \[± standard deviation (SD)\] or median (interquartile range) depending on their distribution. Normality of the variable was assessed by the Kolmogorov--Smirnov test. Parametric \[Student's *t* test or ANOVA (analysis of variance)\] or non-parametric (Mann--Whitney *U* test or Kruskal--Wallis test) tests were used for the comparative analysis of subgroups of patients, according to the distribution of the variables under study. For comparison of data between visits, parametric tests (Student's *t* test for dependent data) or non-parametric tests (Wilcoxon or Friedman tests) were used, depending on the distribution of the variables under study. For the qualitative variables, the Chi-square test or the Fisher exact test were applied to compare subgroups of patients, or the McNemar test for comparisons between visits. A statistical significance level of 0.05 was applied on all statistical tests.

All statistical analyses were performed using the statistical package SAS version 9.4 or later.

Results {#section15-1753466618787385}
=======

The sociodemographic characteristics of the 137 patients included in this study are shown in [Table 1](#table1-1753466618787385){ref-type="table"}. Most patients were female (63.5%) and had developed bronchiectasis as a result of an infectious disease (42.3%). However, for 35% of the patients the aetiology of the disease was unknown. The mean (±SD) time since diagnosis of bronchiectasis was 6.5 ± 7.0 years (range, 0.0--43.7 years). Jet nebulizers were used most frequently (91.2%) for a median of 12.0 min (10.0--15.0) (range: 4.0--50.0).

###### 

Baseline characteristics of the patients, *n* = 137.

![](10.1177_1753466618787385-table1)

  ----------------------------------------------------------------------------------------------------- ----------------
  Age, years, mean ± SD                                                                                 63.0 ± 14.7
  Sex, female, *n* (%)                                                                                  87 (63.5)
  BMI, kg/m^2^, mean ± SD                                                                               24.8 ± 4.1
  Time since diagnosis, mean ± SD                                                                       6.5 ± 7.0
  Relevant cardiopulmonary background, *n* (%)^[1](#table-fn1-1753466618787385){ref-type="table-fn"}^   
   Smoking                                                                                              47 (34.3)
   Hypertension                                                                                         30 (21.9)
   Asthma                                                                                               21 (15.3)
   COPD                                                                                                 19 (13.9)
   Ischaemic heart disease                                                                              5 (3.6)
   Atrial fibrillation                                                                                  5 (3.6)
   Other                                                                                                21 (15.3)
  Cause of bronchiectasis, *n* (%)^[1](#table-fn1-1753466618787385){ref-type="table-fn"}^               
   Bacterial pneumonia                                                                                  31 (22.6)
   Tuberculosis                                                                                         20 (14.6)
   Viral infection                                                                                      7 (5.1)
   COPD                                                                                                 7 (5.1)
   Ciliary dyskinesia                                                                                   6 (4.4)
   Asthma                                                                                               4 (2.9)
   Other                                                                                                19 (13.8)
   Unknown                                                                                              48 (35.0)
  Pulmonary lobes affected, *n* (%)                                                                     
   Localized                                                                                            66 (48.2)
   Generalized                                                                                          71 (51.8)
  Basal FEV1, ml, mean ± SD                                                                             1810.1 ± 639.6
   %, mean ± SD                                                                                         75.8 ± 24.5
  Bronchodilation test (V0)^[2](#table-fn2-1753466618787385){ref-type="table-fn"}^, *n* (%)             
   Positive                                                                                             8 (6.2)
   Negative                                                                                             122 (93.8)
  Symptoms, *n* (%)^[1](#table-fn1-1753466618787385){ref-type="table-fn"}^                              
   Chronic cough                                                                                        135 (98.5)
   Daily mucopurulent expectoration                                                                     133 (97.1)
   Two or more yearly exacerbations                                                                     91 (66.4)
   Dyspnoea                                                                                             72 (52.6)
   Haemoptoic sputum                                                                                    16 (11.7)
   Bronchorrhea (ml/day)                                                                                
    30--50                                                                                              95 (69.3)
    51--100                                                                                             38 (27.7)
    \>100                                                                                               4 (2.9)
  ----------------------------------------------------------------------------------------------------- ----------------

Patients could specify more than one category; percentages calculated over *n* = 137.

The test was considered positive if post-bronchodilation FEV1 values (%) ⩾12% and ⩾200 ml (absolute over basal levels).

BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; SD, standard deviation; V0, visit 0 (basal).

Tolerability to saline solutions {#section16-1753466618787385}
--------------------------------

In the basal visit (V0) the patients were evaluated for their tolerability to HS. According to the tolerability criteria, of the 137 patients enrolled in the study, 92 patients (67.1%) were tolerant and 45 patients (32.9%) were intolerant to HS. The most common complaints by the intolerant patients, as revealed by the questionnaire, were cough, pharyngeal irritation and salty taste. Basal, post-bronchodilator and post-HS FEV1 values were significantly higher (*p* \< 0.01) in tolerant patients than in intolerant patients ([Table 2](#table2-1753466618787385){ref-type="table"}). The patients tolerant to HS at the baseline visit were then advised to remain on this treatment for 4 weeks. The HS-intolerant patients were cited approximately one week later for administration of HS+HA in visit 1 (V1).

###### 

Spirometry measurements, FEV1 (%).

![](10.1177_1753466618787385-table2)

  Basal visit (V0)       Tolerant to HS (*n* = 92)      Non-tolerant to HS (*n* = 45)      *p* value^[1](#table-fn4-1753466618787385){ref-type="table-fn"}^
  ---------------------- ------------------------------ ---------------------------------- ------------------------------------------------------------------
   Basal                 79.7 (25.2)                    67.9 (21.2)                        0.0095
   Post-bronchodilator   83.7 (25.9)                    70.9 (20.9)                        0.0065
   Post-HS               82.4 (26.4)                    67.1 (22.8)                        0.0025
  Visit 1 (V1)           Tolerant to HS+HA (*n* = 31)   Non-tolerant to HS+HA (*n* = 14)   
   Basal                 70.1 (21.2)                    63.9 (22.0)                        0.3913
   Post-bronchodilator   73.4 (20.8)                    65.6 (20.6)                        0.3027
   Post-HS+HA            70.5 (22.4)                    62.2 (25.3)                        0.3032
  Final visit (V2)       Tolerant to HS (*n* = 80)      Tolerant to HS+HA (*n* = 26)       
   Basal                 81.4 (24.2)                    75.2 (22.0)                        0.2976
   Post-bronchodilator   84.5 (24.5)                    78.2 (21.8)                        0.2934
   Post-HS or HS+HA      82.9 (25.2)                    75.9 (21.6)                        0.2407

Mann--Whitney *U* test.

HA, hyaluronic acid; HS, hypertonic saline.

In V1 the 45 patients intolerant to HS were evaluated for their tolerance to HS+HA. We found that, of the 45 patients, 31 patients (68.9%) were tolerant and 14 patients (31.1%) intolerant to the HS+HA solution. The spirometry measurements revealed no significant differences in basal, post-bronchodilator or post-HS+HA for tolerant *versus* intolerant patients ([Table 2](#table2-1753466618787385){ref-type="table"}). The 31 patients tolerant to HS+HA at V1 were instructed to continue treatment for an additional 4 weeks. The 14 patients not tolerant to HS+HA did not continue treatment.

After four weeks of self-administration of HS or HS+HA, the patients were evaluated for their tolerance to either treatment in a final visit. Of the 92 patients initially tolerant to HS in the basal visit, 12 patients ended the treatment before the end of the 4 weeks due to decreased tolerance (8 patients), withdrawal of informed consent (2 patients), or other reasons. Similarly, of the 31 patients tolerant to HS+HA in V1, 5 patients interrupted treatment before the end of the 4 weeks. Of the 45 patients intolerant to HS in the basal visit, 26 patients (57.8%) could complete the 4-week treatment with HS+HA.

Spirometry measurements revealed that the changes in FEV1 (baseline, post-bronchodilator and post-saline solution) observed between the start of the treatment (V0 for HS and V1 for HS+HA) compared to the visit after 4 weeks of treatment were similar in both groups. Although in the group of patients tolerant to HS+HA the percentage improvements of FEV1 were higher (baseline, 1.3%; post-bronchodilator, 1.5%; post-HS+HA inhalation, 1.7%) than the improvements observed in the HS group (baseline, 1.3%; post-bronchodilator, 1.0%; post-HS inhalation, 1.0%), these differences were not statistically significant (baseline, *p* = 0.8528; post-bronchodilator, *p* = 0.6717; post-HS+HA inhalation, *p* = 0.3880, Mann--Whitney *U* test).

Quality of life {#section17-1753466618787385}
---------------

The effectiveness of saline solutions (HS and HS+HA) in terms of QoL was evaluated by comparing the difference between the scores obtained in the QoL-B-Sp-V3.0 and Leicester Questionnaires in the final visit and in the first administration of the saline solution, V0 for HS or V1 for HS+HA. Both treatment groups behaved similarly in seven of the eight dimensions assessed by the QoL-B-Sp-V3.0 Questionnaire ([Table 3](#table3-1753466618787385){ref-type="table"}). For the QoL measured by the Leicester Questionnaire, both groups behaved in a similar manner.

###### 

Percentage of change in quality of life from visits 1 (HS) or 2 (HS+HA) to visit 2, mean (SD).

![](10.1177_1753466618787385-table3)

  --------------------------------------------------------------------------------------------------------------------------------------------
                                  Patients tolerant\   Patients tolerant\   *p-*value^[1](#table-fn6-1753466618787385){ref-type="table-fn"}^
                                  to HS                to HS+HA             
  ------------------------------- -------------------- -------------------- ------------------------------------------------------------------
  QoL-B-Sp-V3.0                                                             

   Physical functioning           11.4 (52.3)          16.8 (40.3)          0.7199

   Role functioning               16.1 (135.4)         9.7 (24.5)           0.1727

   Vitality                       18.7 (86.1)          10.8 (37.6)          0.9243

   Emotional functioning          8.9 (32.8)           5.6 (23.2)           0.7272

   Social functioning             9.8 (59.6)           −5.5 (21.0)          0.4589

   Treatment burden               −16.1 (52.3)         −9.4 (24.9)          0.1447

   Health perceptions             17.9 (47.9)          15.9 (42.8)          0.7783

   Respiratory symptoms           4.4 (20.9)           10.8 (23.2)          0.1270

  Leicester Cough Questionnaire                                             

   Physical domain                11.8 (31.0)          12.1 (18.5)          0.1149

   Psychological domain           7.6 (31.2)           6.9 (25.0)           0.4213

   Social domain                  10.7 (39.0)          10.8 (23.9)          0.2787

   Global                         8.3 (25.2)           11.0 (20.5)          0.1136
  --------------------------------------------------------------------------------------------------------------------------------------------

Mann--Whitney *U* test.

Therapeutic adherence {#section18-1753466618787385}
---------------------

Therapeutic adherence after 4 weeks was evaluated with two tests. First, the Morisky--Green test showed that the patients had a good adherence to the treatment (52.5% of patients tolerant to HS, 61.5% of patients tolerant to HS+HA), and no statistically significant differences were found between the groups (*p* = 0.4212, Chi-square test). Second, the Haynes--Sackett test indicated that 99.1% of the patients presented good treatment compliance, with no statistically significant differences between groups.

Adverse events {#section19-1753466618787385}
--------------

Twenty AEs were reported ([Table 4](#table4-1753466618787385){ref-type="table"}): 9 AEs in the group of patients tolerant to HS (7 with confirmed or probable relationship to treatment) that affected 8 patients; 10 AEs in the group of patients tolerant to HS+HA (7 with confirmed or probable relationship to treatment) that affected 8 patients; and 1 AE in a patient intolerant to saline solutions. Overall, 87.5% of patients who experienced AEs in the group of patients treated with HS had to withdraw from treatment. This percentage was 62.5% in the group of patients treated with HS+HA. Thus, HS+HA generated fewer reactions leading to treatment withdrawal. There were five serious AEs reported by five patients (3.6% of total number of patients included in the study) ([Table 4](#table4-1753466618787385){ref-type="table"}).

###### 

AEs reported during the study, *n* = 137.

![](10.1177_1753466618787385-table4)

  AE                               *N* (patients)   *N* (AEs)   Percentage (AEs)   Serious AE
  -------------------------------- ---------------- ----------- ------------------ ------------
  Decreased FEV1                   1                1           5                  
  Infection                        2                2           10                 2
  Shaking                          1                1           5                  
  Abdominal pain                   1                1           5                  1
  Nausea                           2                2           10                 
  Dry mouth                        1                1           5                  
  Exacerbation of bronchiectasis   1                1           5                  
  Dyspnoea                         2                4           20                 2
  COPD                             1                1           5                  
  Haemoptysis                      1                1           5                  
  Pharyngeal inflammation          2                2           10                 
  Cough                            3                3           15                 
  **Total**                        18               20          100                5

AE, adverse event; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second.

Discussion {#section20-1753466618787385}
==========

In this study we set out to evaluate the tolerability of an inhaled HS solution supplemented with HA 0.1% on patients intolerant to HS 7% alone. We found that 68.9% of patients intolerant to HS 7% could tolerate HS+HA, and 57.8% could continue the treatment for at least four weeks. In this regard, our study achieved its objective and suggests that HA improves tolerability of inhaled HS therapy. In considering the validity and applicability of this finding, several points should be noted.

The FEV1 values at baseline indicated that those patients intolerant to HS alone had worse lung function than those tolerant to HS, suggesting that FEV1 could be a potential predictor of good tolerance to inhaled saline solutions. In this regard, our study shows a similar pattern of a previous work with cystic fibrosis patients, which showed worse tolerance in patients with lower FEV1.^[@bibr13-1753466618787385]^ However, despite their worse lung condition, a large fraction of these patients (68%) could tolerate HS+HA.

Regarding the specific reasons for better tolerance of HS+HA *versus* HS, a previous study of cystic fibrosis patients had shown a statistically significant lower incidence of bronchoconstriction, cough and throat irritation, resulting in a decrease in the use of β~2~ bronchodilators.^[@bibr20-1753466618787385]^ Our study did not detect specific reasons that could explain the higher tolerance of HS+HA in bronchiectasis patients, and this should remain the subject of future investigations. The precise mechanism by which HA reduces the side effects of HS inhalation remains unknown, although HA has been shown to hydrate the airways, attenuate bronchial hyper-responsiveness and reduce inflammation.^[@bibr8-1753466618787385][@bibr9-1753466618787385]--[@bibr10-1753466618787385]^

The goal of our open-label study was to demonstrate, in standard clinical practice, that HS+HA can be tolerated by bronchiectasis patients intolerant to HS. In this regard, our study complements a previous study that showed that up to 81% of cystic fibrosis patients intolerant to HS were tolerant to HS+HA.^[@bibr13-1753466618787385]^

This study has a number of limitations worth mentioning. First, since this was a non-controlled, open-label study, it was subjected to possible biases from physicians and patients, who had to evaluate and quantify parameters which entail a considerable degree of subjectivity. Second, the seven-question, Likert-type questionnaire used to assess tolerability was not validated as a tool for the study of tolerance of inhaled saline solutions, although it was based on the most common AEs of HS reported in previous studies. To our knowledge, no such validated questionnaire has been described. Third, there was no control for possible biases derived from repeated tests of HS solutions: the results of the second visit (to test HS+HA) could be influenced by the experience of the patient in the first (to test HS). However, our study aimed to reflect real-world clinical practice, which is certainly influenced by subjective judgements. Further, our study did not consider population heterogeneity, comorbidities or concomitant medication. Also, the small number of patients analysed limited the statistical analysis of some of the secondary objectives. Finally, our study was limited by the time frame of 4 weeks, which could be insufficient to demonstrate the long-term tolerance of the saline solutions investigated, although it has been observed that most AEs are typically resolved in the first 15 days of treatment.^[@bibr5-1753466618787385]^ We observed that HS+HA treatment generated fewer adverse reactions leading to treatment withdrawal than HS, suggesting a better long-term tolerance. Future randomized, blinded and long-term trials should be carried out to support our hypothesis.

The efficacy of long-term HS therapy in the treatment of bronchiectasis patients is still the subject of debate.^[@bibr4-1753466618787385],[@bibr6-1753466618787385],[@bibr7-1753466618787385],[@bibr21-1753466618787385]^ A 12-month, randomized, double-blind study of bronchiectasis patients in therapy with HS *versus* isotonic saline did not find differences in exacerbations, QoL, sputum colonization or respiratory function.^[@bibr7-1753466618787385]^ However, after study completion, more patients (73%) in this study chose to continue with HS therapy than with isotonic saline therapy. Recent reviews of the available evidence are still inconclusive as to the benefits of inhaled hyperosmolar *versus* isotonic therapies, especially in patients with milder disease, and suggest that future studies are needed in patients with severe disease.^[@bibr21-1753466618787385],[@bibr22-1753466618787385]^ Since initial tolerability is a major factor that limits inhaled HS treatment for many patients, our study shows that HS+HA could greatly increase the number of bronchiectasis patients benefiting from this therapy.

Conclusion {#section21-1753466618787385}
==========

Our study shows that addition of HA to HS could benefit a large fraction of patients that are initially intolerant to HS alone, improving tolerability. The addition of HA could also enhance QoL and adherence to the treatment for bronchiectasis patients.
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